🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care

RecruitingNAAges 18 Years - anyAllNova Scotia Health Authority
NCT07169422 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Type 2 diabetes is the leading cause of chronic kidney disease, which can result in serious complications such as kidney failure and heart disease. Although effective medications exist to slow the progression of kidney damage, they are often underused in primary care, particularly for individuals without a regular family doctor. In response to this gap, 46 community pharmacy-led primary care clinics were launched across Nova Scotia in 2023 to serve under-resourced areas. Pharmacists at these clinics can prescribe for many chronic conditions, but currently not for diabetic kidney disease. To address this, the research team collaborated with kidney, diabetes, and primary care experts, patient partners and regulatory bodies to develop and validate step-by-step prescribing guide (called algorithms) that support pharmacists in identifying and managing diabetic kidney disease. All medications

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults ≥18 years with T2D and DKD (eGFR≥ 30-60 ml/min/1.73m2 and/or UACR≥3 mg/mmol) * Adults who do not have primary care provider, * Adults who are eligible for initiation of treatment with RASi, SGLT2i or nsMRA Exclusion Criteria: * Hypotension * Type 1 diabetes * History of allergy or intolerance to either, renin angiotensin system inhibitor (RASi), SGLT2 inhibitor (SGLT2i) and nonsteroidal mineralocorticoid receptor antagonist (nsMRA). * Already receiving all three medications: RASi, SGLT2i, and nsMRA . * Exceed algorithm thresholds for potassium levels or eGFR less than 30 mL/min/1.73m² * Limited life expectancy of less than 1 year * Followed by a subspecialty physician (e.g., nephrologist or endocrinologist) * Unable to give consent
💊

What it tests

  • Usual care for diabetic kidney disease management without primary care provider.
  • Pharmacist-led validated diabetic kidney disease decision support algorithm.
📍

Where

1 site
Dalhousie University
Halifax, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy